Early diagnosis after the onset of symptoms allows for antiviral treatment. This therapy may reduce the severity and duration of the illness if started within the first 48 hours.
With the actim™ Influenza A&B test, the influenza virus can be diagnosed quickly and reliably on the spot. It allows the right antiviral treatment to be prescribed, while also avoiding the unnecessary use of antibiotics.
Testing hospitalized patients for influenza type A and B prevents the nosocomial transmission of the infection to patients at high risk of influenza-related complications. Thus it can contribute to reduction in the cost and length of hospital stay.
The actim™ Influenza A&B is a rapid qualitative in vitro assay that detects and differentiates between influenza type A and B antigens (nucleoprotein) extracted from the respiratory specimens. The test has been shown to detect various Influenza A subtypes including the avian subtypes H5N3, H7N3, H9N2 and H5N1.
With the simple dipstick test you can diagnose and differentiate influenza A or B types in just 15-20 minutes including sample collection.
